Biotech company Thermo Fisher Scientific has announced plans to acquire Brammer Bio, a viral vector manufacturer for gene and cell therapies, for $1.7 billion.
The Court of Justice of the European Union’s recent refusal to provide further guidance on the full scope of Neurim in a case involving supplementary protection certificates last week has left some big questions unanswered.
A “biotech boom” is underway in the UK, according to a new report from UK investment management firm Downing.
A California-based company which breeds berries has filed a patent infringement claim against a competitor.
The Court of Justice of the European Union yesterday, March 21, handed down a supplementary protection certificate decision referred to it by the English High Court.
Seven new drugs are forecasted to achieve annual sales of $1 billion or more by 2023, according to a new report.
World Health Organization (WHO) experts have called for central registry on human genome editing research is needed, among a committee consensus that it would be irresponsible for any scientist to conduct gene-editing studies in people.
The EU General Court yesterday, March 20, annulled a European Union Intellectual Property Office (EUIPO) decision and handed a trademark victory to Spain-based Prim.
Allergan and the Saint Regis Mohawk Tribe have again urged the US Supreme Court to hear their closely-followed litigation on tribal sovereign immunity, following a submission from generic maker Mylan in the case.
The US Supreme Court will seek the advice of the country’s solicitor general after it agreed to hear an appeal in a dispute over whether a medical treatment is directed towards a natural law.